Purespring Therapeutics has raised £80 million in an oversubscribed Series B financing
LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in...
Obsidian Therapeutics secures $160.5 million in oversubscribed Series C Funding
CAMBRIDGE: Obsidian Therapeutics, Inc., a trailblazer in engineered cell and gene therapies, has successfully completed a $160.5 million Series C financing round. This round was...
Serneke’s rights issue oversubscribed
STOCKHOLM: Serneke Group AB announced that the Company’s subscription ratio in the rights issue amounts to 187 percent. The subscription period for the rights issue...